Pfizer has submitted an application to the FDA for its experimental
cancer medicine Sutent, which is designed to stop the blood supply to
tumor cells and directly attack them.

11 Aug 2005, 17:22 GMT - Pfizer is seeking FDA approval for Sutent as a
treatment for malignant gastrointestinal stromal tumor and metastatic
renal cell carcinoma among patients whose tumors do not respond to, or
do not tolerate standard treatment options. The FDA has granted Sutent
fast-track status since Sutent may provide significant benefit over
existing therapy for serious or life-threatening illnesses for which no
therapy exists.

Sutent is an oral, multi-targeted cancer therapy that combines anti-
angiogenic and anti-tumor activity to simultaneously stop the blood
supply to, and directly attack tumor cells. Over 2,000 patients have
received Sutent as part of Pfizer's clinical trial program.

Sutent also is being studied alone and in combination with other
medicines as a treatment for a number of other solid tumors, including
breast, lung, prostate, and colorectal cancers.

knowledge is power - growing old is mandatory - growing wise is optional    
"Many more men die with prostate cancer than of it. Growing old is
invariably fatal. Prostate cancer is only sometimes so."
http://community.webtv.net/PALMER_ENT/doc